Roanna Ruiz
Stock Analyst at Leerink Partners
(0.90)
# 4,059
Out of 5,239 analysts
61
Total ratings
36.59%
Success rate
-15.34%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRMD CorMedix | Maintains: Outperform | $13 → $14 | $7.51 | +86.42% | 2 | Apr 28, 2026 | |
| CYTK Cytokinetics | Maintains: Outperform | $83 → $84 | $74.81 | +12.28% | 2 | Feb 26, 2026 | |
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $1.61 | +24.22% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $6.26 | +43.77% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.18 | +493.22% | 1 | Apr 28, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $2.41 | -58.51% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $9.40 | +112.77% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $8.63 | +212.86% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $4.16 | +212.50% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $6.61 | +111.80% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $330 | $581.74 | -43.27% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $51.16 | -51.13% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $14.53 | +237.23% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $5.50 | +9.09% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $38.89 | -51.14% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $96.23 | +24.70% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $6.47 | +672.80% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $14.95 | +167.56% | 6 | Oct 19, 2022 |
CorMedix
Apr 28, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $7.51
Upside: +86.42%
Cytokinetics
Feb 26, 2026
Maintains: Outperform
Price Target: $83 → $84
Current: $74.81
Upside: +12.28%
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $1.61
Upside: +24.22%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $6.26
Upside: +43.77%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.18
Upside: +493.22%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $2.41
Upside: -58.51%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $9.40
Upside: +112.77%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $8.63
Upside: +212.86%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $4.16
Upside: +212.50%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $6.61
Upside: +111.80%
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $581.74
Upside: -43.27%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $51.16
Upside: -51.13%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $14.53
Upside: +237.23%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $5.50
Upside: +9.09%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $38.89
Upside: -51.14%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $96.23
Upside: +24.70%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $6.47
Upside: +672.80%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $14.95
Upside: +167.56%